Amakuru

Umuti wa diyabete urashobora kunoza ibimenyetso byindwara ya Parkinson

Lixisenatide, glucagon imeze nka peptide-1 yakira reseptor agonist (GLP-1RA) yo kuvura diyabete, itinda dyskinesia ku barwayi barwaye indwara ya Parkinson hakiri kare, nk'uko byagaragajwe n'ibyavuye mu kizamini cyo mu cyiciro cya 2 cy’amavuriro cyasohotse mu kinyamakuru cyitwa New England Journal of Medicine ( NEJM) ku ya 4 Mata 2024.

Ubushakashatsi buyobowe n’ibitaro bya kaminuza bya Toulouse (Ubufaransa), bwinjije amasomo 156, bigabanywa kimwe hagati y’itsinda rivura lixisenatide n’itsinda rya placebo.Abashakashatsi bapimye ingaruka z’ibiyobyabwenge bakoresheje Sosiyete ya Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) amanota ya III, hamwe n’amanota menshi ku gipimo cyerekana ihungabana rikomeye ry’imodoka.Ibisubizo byagaragaje ko mu kwezi kwa 12, amanota MDS-UPDRS igice cya III yagabanutseho amanota 0.04 (byerekana ko hari iterambere ryoroheje) mu itsinda rya lixisenatide kandi yiyongereyeho amanota 3.04 (byerekana ko indwara ikabije) mu itsinda rya placebo.

Ubwanditsi bwa NEJM bwo muri iki gihe bwagaragaje ko, hejuru, aya makuru yerekana ko lixisenatide yarinze burundu ububi bw’ibimenyetso by’indwara ya Parkinson mu gihe cy’amezi 12, ariko ibyo bishobora kuba ari ibitekerezo birenze urugero.Ibipimo byose bya MDS-UPDRS, harimo Igice cya III, ni umunzani uhuriweho ugizwe n'ibice byinshi, kandi gutera imbere mu gice kimwe bishobora kurwanya kwangirika mu kindi.Byongeye kandi, amatsinda yombi yikigereranyo ashobora kuba yarungukiwe no kwitabira igeragezwa ryamavuriro.Nyamara, itandukaniro riri hagati yaya matsinda yombi yikigereranyo risa nkukuri, kandi ibisubizo bishyigikira ingaruka za lixisenatide ku bimenyetso byindwara za Parkinson hamwe n’amasomo y’indwara.

Ku bijyanye n'umutekano, 46 ku ijana by'amasomo yavuwe na lixisenatide yagize isesemi na 13 ku ijana yagize kuruka. Ubwanditsi bwa NEJM bwerekana ko kuba ingaruka mbi zishobora kubangamira ikoreshwa rya lixisenatide mu kuvura indwara ya Parkinson, bityo hakaba hakomeje gukorwa ubushakashatsi. kugabanya ibipimo nubundi buryo bwo gutabara bwaba bufite agaciro.

"Muri uru rubanza, itandukaniro ry’amanota ya MDS-UPDRS ryagize uruhare rukomeye mu mibare ariko rito nyuma y'amezi 12 avurwa na lixisenatide. Akamaro k'ubwo bushakashatsi ntabwo gishingiye ku bunini bw'impinduka, ahubwo ni uko kerekana."Ubwanditsi bumaze kuvugwa bwanditse bugira buti: "Ikibazo gihangayikishije abarwayi benshi ba Parkinson ntabwo ari uko bameze ubu, ahubwo ni ubwoba bw’iterambere ry’indwara. Niba lixisenatide itezimbere amanota ya MDS-UPDRS ku manota 3, noneho agaciro k’ubuvuzi k’imiti gashobora kuba gake ( cyane cyane bitewe n'ingaruka zayo) Kurundi ruhande, niba efficacy ya lixisenatide ari cumulative, ikongerera amanota andi manota 3 kumwaka mugihe cyimyaka 5 kugeza 10, noneho ibi birashobora kuba imiti ihinduka rwose intambwe ikurikiraho biragaragara ko izakora ibigeragezo igihe kirekire. "

Yakozwe n’uruganda rukora ibiyobyabwenge rw’Abafaransa Sanofi (SNY.US), lixisenatide yemejwe n’ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) cyo kuvura diyabete yo mu bwoko bwa 2 mu 2016, bituma GLP-1RA ya 5 igurishwa ku isi yose. Ukurikije amakuru bivuye mu bigeragezo bivura, ntabwo bigira ingaruka nziza mu kugabanya glucose nka bagenzi bayo liraglutide na Exendin-4, kandi kwinjira ku isoko ry’Amerika byaje nyuma y’ibyabo, bigatuma ibicuruzwa bitagera ikirenge mucya.Mu 2023, lixisenatide yakuwe ku isoko ryo muri Amerika.Sanofi asobanura ko ibyo byatewe n'impamvu z'ubucuruzi aho kuba umutekano cyangwa ibibazo by'ibiyobyabwenge.

Indwara ya Parkinson nindwara ya neurodegenerative igaragara cyane cyane kubantu bakuze ndetse nabakuze, cyane cyane irangwa no kuruhuka guhinda umushyitsi, gukomera no kugenda gahoro, hamwe nimpamvu itaramenyekana.Kugeza ubu, inkingi nyamukuru yo kuvura indwara ya Parkinson ni imiti yo gusimbuza dopaminergique, ikora cyane cyane mu kunoza ibimenyetso kandi ikaba idafite ibimenyetso bifatika byerekana ingaruka z’iterambere.

Ubushakashatsi bwinshi bwibanze bwerekanye ko GLP-1 reseptor agonist igabanya ubwonko.Neuroinflammation itera gutakaza buhoro buhoro ingirabuzimafatizo zikora ubwonko bwa dopamine, ikintu nyamukuru kiranga indwara ya Parkinson.Nyamara, GLP-1 yonyine yakira agoniste ifite ubushobozi bwo kubona ubwonko igira ingaruka mu ndwara ya Parkinson, kandi vuba aha semaglutide na liraglutide, bizwi cyane ku ngaruka zo kugabanya ibiro, ntiberekanye ubushobozi bwo kuvura indwara ya Parkinson.

Mbere, ubushakashatsi bwakozwe n'itsinda ry'abashakashatsi bo mu kigo cya Neurologiya muri kaminuza ya Londere (mu Bwongereza) bwerekanye ko exenatide, imeze nka lixisenatide, yateje imbere ibimenyetso by'indwara ya Parkinson.Ibyavuye mu igeragezwa byagaragaje ko mu byumweru 60, abarwayi bavuwe na exenatide bagabanutseho amanota 1 amanota yabo ya MDS-UPDRS, mu gihe abavuwe na platbo bafite iterambere rya amanota 2.1.Yafatanije na Eli Lilly (LLY.US), uruganda rukora imiti muri Amerika, exenatide ni GLP-1 ya reseptor agonist ya mbere ku isi, yari imaze imyaka itanu yiharira isoko.

Nk’uko imibare ibigaragaza, byibura batandatu GLP-1 yakira reseptor agoniste barageragejwe cyangwa barageragezwa kubera akamaro kabo mu kuvura indwara ya Parkinson.

Ishyirahamwe mpuzamahanga rya Parkinson rivuga ko kuri ubu ku isi hari abarwayi ba Parkinson miliyoni 5.7, mu Bushinwa bagera kuri miliyoni 2.7.Kugeza mu 2030, Ubushinwa buzaba bufite kimwe cya kabiri cy'abatuye Parkinson ku isi.Nk’uko DIResaerch (DIResaerch) ibitangaza, ku isi hose isoko ry’ibiyobyabwenge by’indwara ya Parkinson rizagurishwa miliyari 38.2 mu 2023 bikaba biteganijwe ko rizagera kuri miliyari 61.24 mu 2030.

Igihe cyo kohereza: Apr-24-2024